Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

Plain-language summary

This study observes how chemotherapy decisions are made based on the EndoPredict test in patients with endocrine-sensitive breast cancer. It enrolled patients over 18 with early-stage (Stage I/II), ER-positive and HER2-negative breast cancer. This is a non-phase study and is active but not currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

North Eastern German Society of Gynaecological Oncology

Intervention

Observation

Start date

7/17/2018

Estimated completion

10/1/2032

Countries

Germany, Switzerland

Related genes

Locations

• München, Germany
• Berlin, Germany
• Ansbach, Germany
• Berlin, Germany
• Berlin, Germany
• Berlin, Germany
• Berlin, Germany
• Bremerhaven, Germany
• Chemnitz, Germany
• Dresden, Germany
• Dresden, Germany
• Düsseldorf, Germany
• Ebersberg, Germany
• Erding, Germany
• Fürstenwalde, Germany
• Halle, Germany
• Hamburg, Germany
• Hamburg, Germany
• Herford, Germany
• Hildesheim, Germany
• Jena, Germany
• Koblenz, Germany
• Landshut, Germany
• Magdeburg, Germany
• Magdeburg, Germany
• Marktredwitz, Germany
• Mitte, Germany
• München, Germany
• Oranienburg, Germany
• Pinneberg, Germany
• Potsdam, Germany
• Regensburg, Germany
• Rosenheim, Germany
• Traunstein, Germany
• Trier, Germany
• Wernigerode, Germany
• Wuppertal, Germany
• Bern, Switzerland
• Lucerne, Switzerland
• Zurich, Switzerland

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Informed consent
2. Tested with EndoPredict within the previous 6 months before inclusion
3. Age ≥ 18 years
4. Patients with primary invasive breast cancer, Stage I/II
5. ER-positive
6. HER2-negative
7. N0 or N1 (1-3 positive lymph nodes)
8. T1 - T3

Exclusion Criteria:

1. Inflammatory breast cancer
2. Bilateral breast cancer
3. Breast cancer in the last 10 years
4. Other invasive malignancies in the last 5 years